Application of Chemotherapy in Hematology Malignancies 林建廷 Dec 4, 2007.

Slides:



Advertisements
Similar presentations
Cytidine analogue ALL, AML
Advertisements

BASIC INFORMATION Oncology – the study of the causes, properties, disease progressions and treatments of tumors & cancer Oncologist – physician who specializes.
Extravasation of Chemotherapeutic Agents
Antineoplastics  W hat is Cancer ? Cancer is a disorder of cell division (leading cause of death).  C C ancers most commonly occur in: breast (♀) -
Anticancer and Chemotherapy By: Mohamed Fahad Al-Ajmi.
CHEMOTHERAPY An Overview Amy Sinacola. Haematology Macmillan Clinical Nurse Specialist.
PBL 6 – Lymphoma and leukemia
MICROTEACHING Sanjeev Sharma
Alkylating agents: Platinum analogs Nitrogen Mustards Carboplatin
Antineoplastic Agents Pharmacology II NUR 312. Principles of Chemotherapy  The goal is to eliminate all malignant cells without excessive destruction.
Chapter 49 Antineoplastic Drugs Department of pharmacology Liu xiaokang( 刘小康) 2010,3.
Cancer Chemotherapy Topics
Understanding the cell cycle - chemotherapy and beyond
CANCER CHEMOTHERAPY. General Principles of Action of Anticancer Drugs A. Treatment strategies B. Treatment regimens and scheduling C. Problems associated.
Chemotherapy of Medulloblastoma By: Minh Trinh. Objectives Briefly describe chemotherapy of medulloblastoma Discuss different regimens used for therapy.
Cancer therapy - conventional Surgery Radiotherapy Chemotherapy Adjuvant therapies.
Cancer Drug Classes The classes of drugs currently used in the cancer clinic are  1. DNA Binding Agents (intercalating and alkylating.
PYRAMID POINTS CHAPTER 52: ANTINEOPLASTIC MEDICATIONS.
Anthracycline Side Effects Myelosuppression, dose limiting toxicity leukopenia more common than thrombocytoenia OR anemia Nausea & vomiting Mucositis &
Cancer Chemotherapy: Development of Drug Resistance.
Clinical Division of Oncology Department of Medicine I Mediacal University of Vienna, Austria Principles of chemotherapy.
Patients on Chemotherapy Dr. Feras FARARJEH. General Concepts The purpose of treating cancer with chemotherapeutic agents is to prevent cancer cells from.
II- Antimetabolites.
Treatment of Leukemias and Lymphomas December 2013.
Mosby items and derived items © 2007, 2005, 2002 by Mosby, Inc., an affiliate of Elsevier Inc. Pharmacology in Nursing Antineoplastic Drugs Part 1: Cancer.
 Management varies with type of lymphoma and pt factors (co-morbidities, age, performance status, pt preferences)  Goal of tx can be curative, to prolong.
Treatment of Non- Hodgkin’s Lymphoma. Precursor B cell Lymphoblastic Leukemia Remission induction with combination therapy Consolidation phase: –High.
ANTI-NEOPLASTIC DRUGS
Chemotherapy Agents Jeremy S. Heiner, Ed.D., CRNA.
Cancer Treatment Ashley Panakezham Rosemin Panjwani Osman Jamal Mustafa Quraishi.
Chapter 20 Antineoplastic and Immunosuppressive Drugs Copyright © 2011 Delmar, Cengage Learning.
Principles of Chemotherapy. Objectives At the completion of this session the participant will be able to: ◦ Define combination chemotherapy ◦ Recognize.
Joseph A. De Soto M.D., Ph.D., F.A.I.C.
Microtubule inhibitors
Slide 1 Copyright © 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc. Chapter 44 Drugs Affecting Neoplasms.
© 2004 by Thomson Delmar Learning, a part of the Thomson Corporation. Fundamentals of Pharmacology for Veterinary Technicians Chapter 20 Antineoplastic.
ONCOLOGY Cytotoxic Agents. ONCOLOGY Cytotoxic agents Selective toxicity based on characteristics that distinguish malignant cells from normal cells Antineoplastic.
Principles of Chemotherapy and Chemotherapy Complications Özlem Sönmez, MD Yeditepe University Hospital Section of Medical Oncology.
CHEMOTHERAPY Dr.M.Torfehnezhad Pediatrician Definition: Chemotherapy The treatment of cancer using specific chemical agents or drugs that are destructive.
Clinical Division of Oncology Department of Medicine I Medical University of Vienna, Austria Cytotoxic Agents.
Antineoplastics 1 February :08 AM.
Cancer Chemotherapy Dr.Azarm.  The goal of cancer treatment is eradication of cancer  If not possible shifts to palliation,amelioration and preservation.
Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 101 Anticancer Drugs I: Cytotoxic Agents.
TREATMENT. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Cancer Heather Gates RN, BSN October 20, Core Concepts in Pharmacology, 2e By Norman Holland and Michael Patrick Adams © 2007 Pearson Education,
Therapy of cancer disease This study material is recommended specifically for practical courses from Pharmacology II for students of general medicine and.
Treatment. Phases of treatment Induction chemotherapy Postremission therapy *Initial goal: quickly induce CR *Therapy depends on patient age.
Anticancer Drugs. Introduction Cancer refers to a malignant neoplasm or new growth. Cancer cells manifest uncontrolled proliferation, loss of function.
DEPARTMENT OF PHARMACEUTICS 1. Cancer In most cases, causes of cancer is multifactorial (environmental, genetic) 25% of population of U.S will be diagnosed.
UNIVERSITY OF LUSAKA CANCER CHEMOTHERAPY.
Administration of Chemotherapy
CHEMOTHERAPY An Overview Amy Sinacola.
Anti- CANCER drugs Dr. Mohammed Abd-Almoneim
Microtubule inhibitors
Patients on Chemotherapy
Copyright © 2017, Elsevier Inc. All rights reserved.
Antineoplastic Prescribing I
RTT 335 Patient Care in RTT Chemotherapy.
School of Pharmacy, University of Nizwa
بسم الله الرحمن الرحيم 1.
CHEMOTHERAPY An Overview Amy Sinacola.
Chemotherapy Day 2.
Antitumour Antibiotics PHL 417
PLANT ALKALOIDS Prof.Dr.,NASHAAT LOTFY
Chemotherapy Vipin Patidar
Histopathology Pharmacology Review
ANTIMICROTUBULES PHL 417.
OBJECTIVES To learn the mechanism of cytotoxicity and toxicity of the commonly used antimetabolites.
Overview of TLS What is tumor lysis syndrome ? When does TLS arise?
Presentation transcript:

Application of Chemotherapy in Hematology Malignancies 林建廷 Dec 4, 2007

> > How much do you know about your patient? Disease’s factor –The diagnosis? –Current status? (new case, relapse, refractory) Patient’s factor –Performance status (ECOG) –Co-morbidity? HBV/HCV/HIV? Last MC? –Family support Doctor’s factor –Previous regimen? Effect? Toxicity? –Your plan? The possible toxicity of chemotherapy? Dose adjustment? 2

> > What will happen to the patient in the future? –Disease progression –Treatment complication Tumor lysis syndrome CINV (chemotherapy-induced nausea and vomiting) Mucositis/ diarrhea Infection/ sepsis/ shock Drug toxicity –CR/ PR For example: –AML s/p inductional I3A7 3

> > Tumor lysis syndrome –Spontaneous –Secondary to chemotherapy 4

Tumor Lysis Syndrome  Important risk factors:  High tumor burden  Highly chemo-sensitive  Ex. Acute leukemia, high-grade NHL (Burkitt)  S/S  LDH, K, P, UA, lactic acid  ARF / Seizure / Arrhythmias 5

Tumor Lysis Syndrome(II)  預防勝於治療  UA  K  Lactic acid  Aggressive hydration if tolerated  Urine alkalization, keep urine PH~7.0  Allopurinol/ Rasburicase  Kalimate, Hemodialysis  Cytoreduction before formal chemotherapy 6

> > Chemotherapy metabolism and excretion –Liver/ bile –Kidney 7

CINV (Nausea and Vomiting)  High emetic potential ( >90% ) (1)Cisplatin>50 mg/m2 (2)Dacarbazine (DTIC) (3)Nitrogen mustard (4)Streptozotocin (5)Cyclophosphamide>1500 mg/m2  Moderately high emeticpotential (60~90% ) (1)Carboplatin (2)Cisplatin<50mg/m2 (3)Procarbazine (4)Doxorubicin (5)Cytarabine>1g/m2(6)MTX>1g/m2 8

Premedication for CINV Anti-emesis drugs: Major: 5HT3 antagonist, steroid, NK1- antogonistMajor: 5HT3 antagonist, steroid, NK1- antogonist Minor: Vena, Primperan, Novamin, AtivanMinor: Vena, Primperan, Novamin, Ativan 9

Vascular Access  External devices  Peipheral cath  Central venous catheter (CVP) line  Peripherally inserted central catheters (PICC)  Implanted devices  Port-A  Hickmann 10

Catheter-related Complications  Catheter malfunction  Venous thrombosis (DVT)  Infection 11

Gastrointestinal Toxicity  Stomatitis/ mucositis (1)Methotrexate & 5-FU(2)Concomittant XRT (3)Oral rinses / anagesics / IV fluids (4)Avoid aspiration & treatment of superinfection  Diarrhea (1)IV fluids and nutritional supply (2)Oral opioid / octreotide / loperamide 12

13

Solution Normal saline : Cisplatin, Doxorubicin, Normal saline : Cisplatin, Doxorubicin, Epirubicin, Methotraxate, Vinblastine, Epirubicin, Methotraxate, Vinblastine, Melphalan (phenytoin, heparin ---) Melphalan (phenytoin, heparin ---) D5W : Oxaliplatin, Carboplatin (amphotericin D5W : Oxaliplatin, Carboplatin (amphotericin B, levophed, --) B, levophed, --) 14

Class of Chemotherapy Alkylating agent : mustargen cyclophosphamideifosfomide melphalan chloroambucil busulphan Alkylating agent : mustargen cyclophosphamideifosfomide melphalan chloroambucil busulphan Cisplatin and its analogue : carboplatin oxaliplatin Cisplatin and its analogue : carboplatin oxaliplatin Antimetabolite : methotrexate 5-FUfludarabine 2-CDA gemcitabine Ara-C 6-MP alimta Antimetabolite : methotrexate 5-FUfludarabine 2-CDA gemcitabine Ara-C 6-MP alimta Topoisomerase inhibitor : etoposide (II) irinotecan (I) topotecan (I) Adriamycin (II) Topoisomerase inhibitor : etoposide (II) irinotecan (I) topotecan (I) Adriamycin (II) Antimicrotubule : vinca alkaloid (vincristine, vinblastine, vinorelbine) taxane (paclitaxel, docetaxel) Antimicrotubule : vinca alkaloid (vincristine, vinblastine, vinorelbine) taxane (paclitaxel, docetaxel) 15

Drugs used in the treatment of leukemia/ lymphoma Antimetabolites Alkylating agents DNA binding Mitotic inhibitors Purine analogues Miscellaneous –Corticosteroid, L-asparaginase –Alfa-interferon, ATRA (Transretinoic acid) –Target therapy (Imatinib, rituximab) 16

Antimetabolites Inhibit pyrimidine or purine synthesis or incorporation into DNA Drug Side effect Drug Side effect MTX Mouth ulcer,gut toxicity 6-MP Jaundice Ara-C CNS, cerebellar toxicity, Conjunctivitis Conjunctivitis Hydroxyurea Pigmentation, nail dystrophy, Skin ulcer Skin ulcer 17

Alkylating agents Cross-link DNA, impede RNA formation Drug Side effect Cyclophosphamide Hemorrhagic cystitis, cardiomyopathy cardiomyopathy Busulphan Marrow aplasia, pulmonary fibrosis pulmonary fibrosis BCNU Renal and pulmonary toxicity 18

DNA binding Binding to DNA and interfere with mitosis Drug Side effect Anthracyclines Cardio toxicity Daunorubicin Daunorubicin Adriamycin Adriamycin Mitoxantrone Mitoxantrone Idarubicin Idarubicin Bleomycin(DNA break) Pulmonary fibrosis 19

Mitotic inhibitor Spindle damage, absent metaphase Drug Side effect Vincristine(Oncovin) Neuropathy Vinblastine Vinblastine Vindesine Vindesine 20

Purine analogues Inhibit adenosine deaminase or other purine pathways Drug Side effect Fludarabine Immune suppression, AIHA 2-CDA Renal and neurotoxicity 21

Miscellaneous Corticosteroid : Lymphoblast lysis Peptic ulcer,diabetes,osteoporosis,psychosis Peptic ulcer,diabetes,osteoporosis,psychosis L-Asparaginase: Deprive cells of asparagine Hypersensitivity, low albumin and coagulation factors, pancreatitis Hypersensitivity, low albumin and coagulation factors, pancreatitis VP-16: Mitotic inhibitor Oral ulcer Oral ulcer Alfa-interferon: activate RNAase & natural killer activity Flu-like symptom, thrombocytopenia, leukopenia Flu-like symptom, thrombocytopenia, leukopenia ATRA: Induce differentiation Liver dysfunction,skin hyperkeratosis, leukocytosis, ATRA syndrome Liver dysfunction,skin hyperkeratosis, leukocytosis, ATRA syndrome 22

Alkylating agent Cyclophosphamide and Ifosphamide: Early Hemorrhagic cystitis Early Hemorrhagic cystitis Mesna and keep high urine output –Mesna dose = 1.0 to 1.5  dose of Cyclophosphamide and Ifosphamide (before, after 4hr/ 8hr) 23

24

Methotrexate (1) Toxicity : Myelosuppression Mucositis Renal toxicity and liver toxicity Neurotxicity : systemic : acute cerebral dysfunction intrathecal : acute arachnoiditis subacute arachnoididitis chronic encephalopathy Only one drug for serum level 25

Methotrexate(2) Hydration : 12 hours before MTX, hrs after stopping MTX, keep u/o cc/day Urine alkalinization : keep PH>7.0 LV rescue : hours after finishing MTX, 10-15mg (60-100mg) iv q6h Keep LV rescue to MTX < 0.05μmol/ L. Keep LV rescue to MTX < 0.05μmol/ L. 26

High dose Ara-C: –Cerebellar toxicity (ataxia) –skin rash –conjunctivitis Prophylactic steroid use for skin rash and conjunctivitis Ara-C 27

Vincristine Vincristine (Oncovin): –Peripheral neuropathy –Autonomic neuropathy (ileus) –“NO” bone marrow suppression –Total dose: 2mg in one cycle 28

Doxorubicin Doxorubicin –CHF (DCM): irreversible –Dose-responsive effect rare if cumulative dose < 450 mg/m rare if cumulative dose < 450 mg/m 2 550mg/m2  7% 600mg/m2  15% 700mg/m2  30% –EKG, Cardiac echo f/u 29

L-Asparaginase L-Asparaginase: hydrolyzes asparagine into aspartic acid, kills cells that cannot synthesize asparagine L-asparagine : nonessential amino acid lack of synthesis in lymphoid malignancy lack of synthesis in lymphoid malignancy  AE  Allergy rxn/ pancreatitis/ hyperglycemia/ dyslipidemia/ coagulopathy  Testing dose  “NO” bone marrow suppression 30

Complications of Treatment  Extravasation  Anaphylaxis  Myelosuppression  GI toxicity  Tumor lysis syndrome  Interstitial pneumonitis  Hemorrhagic cystitis 31

Class of Skin Toxicity Vesicants : Vesicants : Anthracycline : Doxorubicin, Epirubicin Vinca alkaloid : Vincristine, Vinblastine Mitomycin-C Anthracycline : Doxorubicin, Epirubicin Vinca alkaloid : Vincristine, Vinblastine Mitomycin-C Irritants : Etoposide, BCNU, DTIC, Cisplatin Paclitaxel, Mitoxantrone Irritants : Etoposide, BCNU, DTIC, Cisplatin Paclitaxel, Mitoxantrone 32

Guidelines for Administration of Vesicant Drugs 1.Ensure patency of a peripheral line (Keep visualization) 2.Avoid dorsal hands or near joints 3.Avoid limbs with impaired circulation 4.Central line in preferred, especially for continuous infusion 5. Test the line in advance 6.Patient’s sensation / Observe local condition 33

Management of Extravasation Stop injection Stop injection Extract drug before removing the Extract drug before removing the catheter, Avoid pressure on the site catheter, Avoid pressure on the site Heat pack : Vinblastine, Vincristine Heat pack : Vinblastine, Vincristine Cold pack : others Cold pack : others Surgery : consult surgeon in persistent Surgery : consult surgeon in persistent pain (>72 hours) or local necrosis pain (>72 hours) or local necrosis Antidote Antidote 34

Antidotes for Extravasation of Cytotoxic Drugs Anthracycline Ice packs DMSO MitomycinDMSO Mechlorethamine(CDDP) Sodium thiosulfate Vinca alkaloid (Etoposide) Warm packs Hyaluronidase Paclitaxel Ice packs Hyaluronidase 35

Other things you should watch out Body weight and urine output Vital signs Intake and nutrition Oral cavity and self-hygiene Blood CBC, DC and biochemistry (Sugar and K) Blood CBC, DC and biochemistry (Sugar and K + ) Mood and emotional change 36